Acadia Pharma (ACAD) Tops Q2 EPS by 2c, provides guidance

Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $242 million versus the consensus estimate of $235.81 million.

GUIDANCE:

Acadia Pharma sees FY2024 revenue of $930-980 million, versus the consensus of $954.2 million.

NUPLAZID net product sales guidance is increased to a range of $590 to $610 million from the previous range of $560 to $590 million, reflecting stronger underlying demand driving recent higher unit volume.
DAYBUE net product sales guidance is decreased to a range of $340 to $370 million from the previous range of $370 to $420 million.

R&D expense guidance is narrowed to the lower end of the previous range and is now expected to be between $305 to $315 million.
SG&A expense guidance is narrowed to the higher end of the previous range and is now expected to be between $465 to $480 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c